Mr Carl R Cutshall, PA | |
153 Maple St, Bangor, ME 04401-4031 | |
(207) 942-8790 | |
Not Available |
Full Name | Mr Carl R Cutshall |
---|---|
Gender | Male |
Speciality | Physician Assistant - Medical |
Location | 153 Maple St, Bangor, Maine |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1932280559 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2082S0105X | Plastic Surgery - Surgery Of The Hand | ME337 (Maine) | Secondary |
363AM0700X | Physician Assistant - Medical | PA337 (Maine) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Carl R Cutshall, PA 153 Maple St, Bangor, ME 04401-4031 Ph: (207) 942-8790 | Mr Carl R Cutshall, PA 153 Maple St, Bangor, ME 04401-4031 Ph: (207) 942-8790 |
News Archive
Gentium S.p.A. announced today that results from the Company's Phase II/III Pediatric Prevention trial and Phase III Treatment trial for Defibrotide of Hepatic Veno-Occlusive Disease will be presented at American Society of Hematology Conference (ASH), December 5-8 in New Orleans.
Just like a comic book super hero, you could say that the enzyme superoxide dismutase (SOD1) has a secret identity. Since its discovery in 1969, scientists believed SOD1's only role was to protect living cells against damage from free radicals. Now, researchers at the Johns Hopkins Bloomberg School of Public Health have discovered that SOD1 protects cells by regulating cell energy and metabolism. The results of their research were published January 17, 2013, in the journal Cell.
Dr. Marisa Weiss, president and founder of Breastcancer.org and a breast oncologist in the Philadelphia area submitted a letter to the U.S. Food and Drug Administration prior to the Oncology Drug Advisory Committee (ODAC) meeting to review data for Avastin's use in metastatic HER2-negative breast cancer. In light of today's news that the FDA has recommended removing Avastin's approval to treat breast cancer, Breastcancer.org is making public Dr. Weiss' ODAC letter in its entirety.
A study by researchers Ra-l M-ndez, ICREA Research Professor at the Institute for Research in Biomedicine (IRB Barcelona) and Pilar Navarro at the IMIM (Institut de Recerca Hospital del Mar, Barcelona) describes a new reprogramming mechanism for the expression of genes responsible for turning a healthy cell into a tumor cell.
› Verified 2 days ago